Uriel Sandkovsky, MD
Infectious Disease · Dallas, TXNPI 1104060904
Payments from drug & device makers
Across 914 payments — averaging $674.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$104K
- Viiv Healthcare Company$97K
- Johnson & Johnson$89K
- Shionogi Inc$87K
- Astrazeneca UK Limited$72K
- Aimmune Therapeutics, Inc.$53K
- plus $116K from 29 others
What the payments were for
- Consulting fees$66,62121%
- Speaking & faculty fees$211,70166%
- Travel & lodging$21,2717%
- Food & beverage$19,8976%
- Education$4890%
- Gifts$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 38 | $103,834 |
| Viiv Healthcare Company | 265 | $96,782 |
| Johnson & Johnson(2 entities) | 33 | $89,026 |
| Shionogi Inc | 101 | $86,713 |
| Astrazeneca UK Limited | 3 | $71,951 |
| Aimmune Therapeutics, Inc. | 40 | $52,568 |
| AstraZeneca | 1 | $51,872 |
| Paratek Pharmaceuticals, Inc. | 87 | $51,559 |
| Tetraphase Pharmaceuticals, Inc. | 21 | $4,587 |
| Insmed, Inc. | 47 | $1,038 |
| Gilead | 43 | $950 |
| Merck | 40 | $887 |
| Astellas Pharma US Inc | 27 | $719 |
| EMD Serono, Inc. | 32 | $527 |
| Napo Pharmaceuticals Inc | 17 | $445 |
| AbbVie | 22 | $443 |
| Novocure Inc. | 1 | $413 |
| Cumberland Pharmaceuticals, Inc. | 19 | $315 |
| Ferring Pharmaceuticals Inc. | 11 | $295 |
| Saol Therapeutics Inc. | 1 | $290 |
| La Jolla Pharmaceutical Company | 10 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $173 |
| Mayne Pharma Commercial LLC | 9 | $160 |
| Theratechnologies Inc. | 10 | $156 |
| Octapharma USA, Inc. | 4 | $104 |
| Melinta Therapeutics, LLC | 7 | $99 |
| Amgen | 5 | $96 |
| Hospira, Inc. | 4 | $69 |
| VBI Vaccine (delaware) Inc. | 1 | $29 |
| KCI USA, Inc. | 2 | $26 |
| Amarin Pharma, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $11 |
| Dynavax Technologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$616,404 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 22 | $320,321 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 56 | $222,592 |
| NuzyraOmadacycline Tosylate | 15 | $172,789 |
| FetrojaCefiderocol Sulfate Tosylate | 27 | $145,698 |
| CresembaIsavuconazonium Sulfate | 19 | $124,741 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $90,541 |
| DovatoDolutegravir Sodium/Lamivudine | 27 | $78,510 |
| Daptomycin | 105 | $64,597 |
| ErtapenemErtapenem Sodium | 129 | $59,101 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $55,285 |
| DescovyEmtricitabine/Tenofov Alafenam | 18 | $38,650 |
| ZerbaxaCeftolozane/Tazobactam | 11 | $32,562 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $29,582 |
| TivicayDolutegravir Sodium | 12 | $26,888 |
| CeftriaxoneCeftriaxone Sodium | 126 | $15,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $1,038 | $320,32122 claims |
| GileadBiktarvy, Descovy | $950 | $261,24374 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Tivicay | $96,782 | $195,93952 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $51,559 | $172,78915 claims |
| Shionogi IncFetroja | $86,713 | $145,69827 claims |
| Astellas Pharma US IncCresemba | $719 | $124,74119 claims |
| MerckZerbaxa | $887 | $32,56211 claims |
| Grifols USA, LLCGamunex-C | $21 | $29,58214 claims |
| Tetraphase Pharmaceuticals, Inc.Xerava | $4,587 | $9,64411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Dallas
- Mezgebe BerheDallas$11M
- Mamta JainDallas$3.7M
- Elizabeth RaceDallas$1.5M
- David GreenbergDallas$1.2M
- Roger BedimoDallas$976K
- Theodoros KelesidisDallas$715K
- Jeremy ChowDallas$500K
- Satish MocherlaDallas$417K
- Edward DominguezDallas$178K
- Tawanda GumboDallas$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.